Less Ads, More Data, More Tools Register for FREE

PureTech founder steps down as CEO to lead SeaPort spin-off

Tue, 09th Apr 2024 07:48

(Sharecast News) - Clinical-stage biotherapeutics group PureTech has announced that its founding chief executive is to step down to lead SeaPort Therapeutics, a PureTech company she founded that has just raised $100m in Series A financing.

Seaport will be led by Daphne Zohar, who has run PureTech since its foundation in 2005, along Steven Paul, the former CEO of Karuna Therapeutics - the PureTech spin-off that was acquired by Briistol Myers Squibb for $14bn earlier this year.

Seaport was established by PureTech to advance certain neuropsychiatric programs and will be 61.5% owned by the company following the Series A.

PureTech said it has internally advanced Seaport's neuropsychiatric medicines programs "to a key inflection point such that the pipeline can now drive value for PureTech through an equity stake and license consideration". As such, PureTech can now share the costs of later-stage development with outside investors and direct additional resources elsewhere in the business.

This same approach, part of PureTech's 'hub-and-spoke strategy', has resulted in $1.1bn in gross proceeds so far from its stake in Karuna. PureTech still receives royalties from Karuna as well as certain milestone payments.

As part of the transition, Zohar will formally step down from the board but stay on as a senior advisor, while long-term PureTech senior executive and biotech veteran Bharratt Chowrira will succeed her as CEO, effective Tuesday.

Meanwhile, Eric Elenko, a PureTech co-founder and current chief innovation officer, has been promoted to the role of president.

"I am excited to step into the CEO role and to lead PureTech through this next phase of its evolution," Chowrira said.

"We have demonstrated the evergreen success of our hub-and-spoke R&D model of venture creation, where we are able to recycle proceeds from our founded entities into both the funding of our current and future programs to change patients' lives and capital returns for shareholders."

PureTech

Shares in this article

Related News

DIRECTOR DEALINGS: PureTech Health directors buy GBP176,000 in shares
1 day ago

DIRECTOR DEALINGS: PureTech Health directors buy GBP176,000 in shares

(Alliance News) - The following is a round-up of share dealings by London-listed company directors and managers announced on Thursday and not separate...

PureTech launches Celea Therapeutics with USD180 million financing
2 Jul 2026

PureTech launches Celea Therapeutics with USD180 million financing

(Alliance News) - PureTech Health PLC on Thursday said its founded entity Celea Therapeutics Inc has completed a USD180 million financing, which will ...

PureTech-founded Seaport reports positive GlyphAgo phase 1 data
9 Jun 2026

PureTech-founded Seaport reports positive GlyphAgo phase 1 data

(Alliance News) - PureTech Health PLC on Tuesday highlighted positive phase 1 data from Seaport Therapeutics Inc for GlyphAgo, supporting plans to adv...